Pliant Therapeutics Inc (PLRX) Stock Price, Quote & News

Company Profile

Pliant Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing integrin-based therapeutics for the treatment of solid tumors. The company's lead product candidate is the PLN-101095, an oral, small molecule dual inhibitor of avß8 and avß1 integrins that is in Phase 1a/1b for the treatment of solid tumors. It is also developing drug discovery platform comprising proprietary library of over 15,000 integrin binding molecules, focusing on integrin-based t...

Industry: Biotechnology

Sector: Healthcare

Phone: 650 481 6770

Website: pliantrx.com

Address:

331 Oyster Point Boulevard, South San Francisco, United States

ulysses1000 Aug. 19 at 12:54 AM

$PLRX Nice FDA Fast track news

0 · Reply

keywestbitcoin Aug. 18 at 5:27 PM

$PLRX buy yes and hold for $2

0 · Reply

notreload_ai Aug. 18 at 3:10 PM

$PLRX receives FDA Fast Track for oral PLN-101095 + Keytruda in ICI-refractory solid tumors. Cash runway into 2H 2028; data expected 2027. https://notreload.xyz/xy/plrx-gets-fda-fast-track-for-pln-101095-in-solid-tumors/

0 · Reply

Stef_DL Aug. 18 at 2:44 PM

$PLRX Good FDA news, and it's up nog even 5%... wa.. what? Does this stonk knows it's a biotech stock 🧐...?

0 · Reply

Stock_Catcher Aug. 18 at 12:30 PM

$PLRX Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

0 · Reply

The_Matrix_reloaded_2020 Aug. 14 at 4:06 PM

$PLRX Just go to $1.25 please so i can get out of here already 🙃

0 · Reply

ToTheMoonTT Aug. 14 at 12:24 AM

$PLRX easy short, Sub $1 is days away.

0 · Reply

Lukey63 Aug. 13 at 5:26 PM

$PLRX Trading at 40% of cash and TBV and 2-yr runway. I am all-in as I have found such opportunities are usually fruitful.

0 · Reply

Biotech_Pharma_Investor Aug. 12 at 8:42 AM

$PLRX 1st patient dosed April 30. It is already 3 full months since then and trial has been enroling faster than planned. First data shouldnt be too late in 2027. Maybe in AACR? (April 2027) or ASCO (June 2027) + new target indications to be announced within 2026. Best case scenario announcement comes with a PIPE/deal? Lots of things that can go well. Worst case scenario: not much news in 2026 + FORTIFY Trial data dissapoint and downside risk somwhat limited by cash cushion. Risk reward seems very favorable

0 · Reply

Biotech_Pharma_Investor Aug. 11 at 8:13 PM

$PLRX - As of June 30, 2026, the Company had cash, cash equivalents and short-term investments of $159.6 million which the Company expects to be sufficient to fund operations into the second half of 2028. - Enrollment remains strong, progressing ahead of schedule. Interim data is expected in 2027. - Pliant plans to provide additional detail on the platform and path forward, including initial treatment indications, in the second half of 2026. Currently trading at around $66M valuation

1 · Reply

Pliant Therapeutics receives Fast Track designation from FDA for PLN-101095

$Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors$

Aug 18, 2026, 8:30 AM EDT - 1 day ago

Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

2026-08-17T11:12:09.000Z - 2 days ago

Pliant Therapeutics reports Q2 EPS (36c), consensus (34c)

Aug 11, 2026, 4:05 PM EDT - 7 days ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2026 Financial Results

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Pliant Therapeutics Quarterly report: Q2 2026

Aug 11, 2026, 7:00 AM EDT - 8 days ago

Pliant Therapeutics Earnings release: Q2 2026

Jul 13, 2026, 8:30 AM EDT - 5 weeks ago

Pliant Therapeutics Names Flavia Borellini, Ph.D. and Robert Iannone, M.D.

May 21, 2026, 5:29 PM EDT - 3 months ago

Pliant Therapeutics Announces Upcoming Presentation at the 2026 American Society of Clinical Oncology Annual Meeting

May 19, 2026, 11:30 AM EDT - 3 months ago

Pliant Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-11T20:57:49.000Z - 3 months ago

Pliant Therapeutics reports Q1 EPS (32c), consensus (36c)

May 11, 2026, 4:05 PM EDT - 3 months ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2026 Financial Results

May 11, 2026, 4:00 PM EDT - 3 months ago

Pliant Therapeutics Earnings release: Q1 2026

May 11, 2026, 4:00 PM EDT - 3 months ago

Pliant Therapeutics Quarterly report: Q1 2026

May 6, 2026, 8:30 AM EDT - 3 months ago

Pliant Therapeutics to Participate in the RBC Capital Markets Global Healthcare Conference

2026-04-30T13:41:08.000Z - 3 months ago

Pliant Therapeutics doses first participant in FORTIFY expansion trial

$Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors$

Apr 30, 2026, 8:30 AM EDT - 3 months ago

Pliant Therapeutics Announces First Patient Dosed in FORTIFY, the Phase 1b Indication Expansion Trial Evaluating PLN-101095 in Patients with ICI-Refractory Solid Tumors

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Pliant Therapeutics Proxy statement: Proxy filing

Apr 22, 2026, 8:00 AM EDT - 4 months ago

Pliant Therapeutics Proxy statement: Proxy filing

2026-04-19T17:00:49.000Z - 4 months ago

Pliant announces presentation of updated data from Phase 1 trial of PLN-101095

$Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting$

Apr 18, 2026, 1:31 PM EDT - 4 months ago

Pliant Therapeutics Announces Presentation of Updated Data from the Phase 1 Trial of PLN-101095 in Patients with ICI-Refractory Solid Tumors at the 2026 AACR Annual Meeting

2026-03-30T22:05:10.000Z - 5 months ago

Pliant Therapeutics files $300M mixed securities shelf

Mar 30, 2026, 8:00 AM EDT - 5 months ago

Pliant Therapeutics Registration statement: Registration filing

Mar 18, 2026, 9:00 AM EDT - 5 months ago

Pliant Therapeutics Announces Upcoming Presentation of Phase 1 Clinical Trial of PLN-101095 in Patients with Solid Tumors at the 2026 AACR Annual Meeting

2026-03-13T11:10:14.000Z - 5 months ago

Pliant Therapeutics price target lowered to $3 from $4 at Canaccord

2026-03-12T11:10:41.000Z - 5 months ago

Pliant Therapeutics price target lowered to $3 from $4 at Piper Sandler

Mar 11, 2026, 5:00 PM EDT - 5 months ago

Pliant Therapeutics Annual report: Q4 2025

Mar 11, 2026, 5:00 PM EDT - 5 months ago

Pliant Therapeutics Earnings release: Q4 2025

2026-03-11T20:27:59.000Z - 5 months ago

Pliant Therapeutics reports Q4 EPS (38c), consensus (38c)

Mar 11, 2026, 4:05 PM EDT - 5 months ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2025 Financial Results

Feb 25, 2026, 2:40 PM EST - 6 months ago

Pliant Therapeutics Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 23, 2026, 8:00 AM EST - 6 months ago

Pliant Therapeutics to Participate in the Oppenheimer Healthcare Life Science Conference

Dec 4, 2025, 12:30 PM EST - 9 months ago

Pliant Therapeutics Transcript: Piper Sandler 37th Annual Healthcare Conference

Dec 4, 2025, 12:30 PM EST - 9 months ago

Pliant Therapeutics Slides: Piper Sandler 37th Annual Healthcare Conference

2025-12-04T12:35:15.000Z - 9 months ago

Pliant Therapeutics announces interim data from PLN-101095

$Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Dec 4, 2025, 7:30 AM EST - 9 months ago

Pliant Therapeutics Announces Interim Data from PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Dec 1, 2025, 8:30 AM EST - 9 months ago

Pliant Therapeutics to Participate in the Piper Sandler Healthcare Conference

2025-11-06T23:45:29.000Z - 10 months ago

Pliant Therapeutics reports Q3 EPS (43c), consensus (52c)

Nov 6, 2025, 4:05 PM EST - 10 months ago

Pliant Therapeutics Provides Corporate Update and Reports Third Quarter 2025 Financial Results

Nov 6, 2025, 4:00 PM EST - 10 months ago

Pliant Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 4:00 PM EST - 10 months ago

Pliant Therapeutics Earnings release: Q3 2025

2025-10-10T09:05:07.000Z - 11 months ago

Pliant Therapeutics downgraded to Underweight from Neutral at JPMorgan

2025-08-10T18:10:14.000Z - 1 year ago

Pliant Therapeutics price target raised to $1.70 from $1.50 at Citi

2025-08-08T11:16:07.000Z - 1 year ago

Pliant Therapeutics price target lowered to $4 from $17 at Piper Sandler

2025-08-07T21:40:19.000Z - 1 year ago

Pliant Therapeutics reports Q2 EPS (71c), consensus (68c)

Aug 7, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Pliant Therapeutics Earnings release: Q2 2025

Aug 7, 2025, 4:00 PM EDT - 1 year ago

Pliant Therapeutics Quarterly report: Q2 2025

Jun 27, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Provides Update on BEACON-IPF

May 21, 2025, 4:03 PM EDT - 1 year ago

Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference

2025-05-08T21:45:41.000Z - 1 year ago

Pliant Therapeutics reports Q1 EPS (92c), consensus (62c)

2025-05-08T20:50:13.000Z - 1 year ago

Pliant Therapeutics reports Q1 EPS (92c), consensus (75c)

May 8, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results

May 8, 2025, 4:00 PM EDT - 1 year ago

Pliant Therapeutics Earnings release: Q1 2025

May 8, 2025, 4:00 PM EDT - 1 year ago

Pliant Therapeutics Quarterly report: Q1 2025

2025-05-01T21:00:50.000Z - 1 year ago

Pliant Therapeutics to reduce workforce by 45%

May 1, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 11, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 10, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Proxy statement: Proxy Filing

Apr 7, 2025, 4:05 PM EDT - 1 year ago

Pliant Therapeutics Announces Upcoming Presentations at the 2025 American Thoracic Society International Conference

$Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors$

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Pliant Therapeutics Announces Interim Phase 1 Data for PLN-101095 in Patients with Immune Checkpoint Inhibitor-Refractory Advanced Solid Tumors

Mar 13, 2025, 7:20 AM EDT - 1 year ago

Pliant Therapeutics Adopts Limited Duration Stockholder Rights Agreement

Mar 3, 2025, 4:05 PM EST - 1 year ago

Pliant Therapeutics Provides Corporate Update and Reports Fourth Quarter 2024 Financial Results

Mar 3, 2025, 10:00 AM EST - 1 year ago

Pliant Therapeutics Earnings release: Q4 2024

Mar 3, 2025, 10:00 AM EST - 1 year ago

Pliant Therapeutics Annual report: Q4 2024

Mar 3, 2025, 9:27 AM EST - 1 year ago

Pliant Therapeutics Provides Update on BEACON-IPF, a Phase 2b/3 Trial in Patients with Idiopathic Pulmonary Fibrosis

ulysses1000 Aug. 19 at 12:54 AM

$PLRX Nice FDA Fast track news

0 · Reply

keywestbitcoin Aug. 18 at 5:27 PM

$PLRX buy yes and hold for $2

0 · Reply

notreload_ai Aug. 18 at 3:10 PM

0 · Reply

Stef_DL Aug. 18 at 2:44 PM

$PLRX Good FDA news, and it's up nog even 5%... wa.. what? Does this stonk knows it's a biotech stock 🧐...?

0 · Reply

Stock_Catcher Aug. 18 at 12:30 PM

$PLRX Pliant Therapeutics Receives FDA Fast Track Designation for PLN-101095 in Combination with Pembrolizumab for the Treatment of ICI-Refractory Solid Tumors

0 · Reply

The_Matrix_reloaded_2020 Aug. 14 at 4:06 PM

$PLRX Just go to $1.25 please so i can get out of here already 🙃

0 · Reply

ToTheMoonTT Aug. 14 at 12:24 AM

$PLRX easy short, Sub $1 is days away.

0 · Reply

Lukey63 Aug. 13 at 5:26 PM

$PLRX Trading at 40% of cash and TBV and 2-yr runway. I am all-in as I have found such opportunities are usually fruitful.

0 · Reply

Biotech_Pharma_Investor Aug. 12 at 8:42 AM

0 · Reply

Biotech_Pharma_Investor Aug. 11 at 8:13 PM

1 · Reply

EarnerVonBraun Aug. 5 at 8:36 PM

$PLRX Reversal begins sometime between tomorrow, Thursday, and Monday next week.

0 · Reply

ToTheMoonTT Aug. 2 at 1:32 AM

$PLRX i shorted and expected to go lower.

0 · Reply

Chuckyboss1 Jul. 22 at 6:52 PM

$PLRX 170 million in cash on hand here trading at 70 million market cap 100 million free money Wall Street bets and discord love these plays read there 10a

0 · Reply

PaulFrench1 Jul. 22 at 9:10 AM

$PLRX One of my favorite biotech setups right now. From a technical perspective, I&#39;m seeing a very promising chart: ✅ Two consecutive bullish Kijun-sen signals. ✅ Two consecutive bullish RSI divergences, suggesting that the long-term downtrend may be coming to an end as selling pressure continues to fade. The price has been building a solid base, and the current structure looks increasingly constructive. From a fundamental perspective, PLRX also stands out: • Strong cash position with an estimated runway of around 2 years. • Advanced clinical pipeline with several meaningful catalysts ahead. • Relatively low dilution risk compared to many small-cap biotech peers. • Overall financial risk appears limited. I only buy when technicals and fundamentals align, and PLRX is one of the few biotech names currently checking both boxes. Not financial advice just my opinion. Always do your own research. 😉

2 · Reply

SQUEAKSBANDIT Jul. 21 at 4:04 PM

$PLRX ugly an ATL with the xbi up today and near 52w highs there is simply no interest in this name really wish they would sell to tang or at least engage in conversation with him

0 · Reply

Paulfrench Jul. 19 at 1:47 PM

$PLRX One of my favorite biotech setups right now. From a technical perspective, I'm seeing a very promising chart: ✅ Two consecutive bullish Kijun-sen signals. ✅ Two consecutive bullish RSI divergences, suggesting that the long-term downtrend may be coming to an end as selling pressure continues to fade. The price has been building a solid base, and the current structure looks increasingly constructive. From a fundamental perspective, PLRX also stands out: • Strong cash position with an estimated runway of around 2 years. • Advanced clinical pipeline with several meaningful catalysts ahead. • Relatively low dilution risk compared to many small-cap biotech peers. • Overall financial risk appears limited. I only buy when technicals and fundamentals align, and PLRX is one of the few biotech names currently checking both boxes. Not financial advice just my opinion. Always do your own research. 😉

2 · Reply

MaskMaker Jul. 19 at 3:59 AM

$PLRX

0 · Reply

ka1954 Jul. 15 at 12:34 PM

$PLRX is this fucking going to stay dead forever? it seems like forever when i bought it

0 · Reply

Biotech_Pharma_Investor Jul. 14 at 3:38 PM

$PLRX PIPE for the integrin platform? (lots of PIPEs everywhere)

0 · Reply

nUme22 Jul. 10 at 2:51 PM

$TRAX money laundering scheme.. Seems way too many in BIO space.. $PLRX couple of yrs back. There are way too many like these Shorting wont work here till the weakness showed, there will be 50% drop suddenly..

0 · Reply

jackcoltrain Jul. 4 at 10:47 PM

$ENGN $PLRX I think better than holding cash in a savings account for this year

0 · Reply

Stef_DL Jun. 28 at 8:27 PM

$PLRX I have been wondering that myself. AI says: --- Pipeline Advancement: Progress and favorable safety/efficacy data from the ongoing FORTIFY trial, which is evaluating PLN-101095 in patients with immune-checkpoint-inhibitor (ICI)-refractory advanced or metastatic solid tumors. Strategic Partnerships & Buyouts: As a clinical-stage, pre-revenue company, securing a major pharmaceutical partnership or being acquired would immediately inject capital and validate their integrin-targeting technology platform. Macroeconomic Conditions & Sector Sentiment: Because Pliant is heavily reliant on future financing and trial outcomes, any easing of monetary policy (interest rate cuts) or a broader biotech sector rally would improve capital access and lift the stock. Investors remain cautious due to past trial discontinuations (such as the BEACON-IPF trial), but Pliant maintains enough capital to fund their operations and upcoming data readouts into the second half of 2028. So maybe a bit..?

0 · Reply

Market Cap	68.11M
Revenue (ttm)	0.00
Net Income (ttm)	-149.34M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	1,373,000
Avg Vol	516,024
Day's Range	N/A - N/A
Shares Out	61.92M
Stochastic %K	62%
Beta	1.24
Analysts	Hold
Price Target	$2.50